Vaxcyte: VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 (NASDAQ:PCVX)
· seekingalpha.com
Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead. Click for more on PCVX.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...